Zoledronate alleviates subchondral bone collapse and articular cartilage degeneration in a rat model of rotator cuff tear arthropathy.

IF 7.2 2区医学 Q1 ORTHOPEDICS

Osteoarthritis and Cartilage Pub Date : 2024-08-15 DOI:10.1016/j.joca.2024.08.005

Hiroki Tawaratsumida, Tomohiro Iuchi, Yusuke Masuda, Takayuki Ide, Shingo Maesako, Takasuke Miyazaki, Toshiro Ijuin, Shingo Maeda, Noboru Taniguchi

{"title":"Zoledronate alleviates subchondral bone collapse and articular cartilage degeneration in a rat model of rotator cuff tear arthropathy.","authors":"Hiroki Tawaratsumida, Tomohiro Iuchi, Yusuke Masuda, Takayuki Ide, Shingo Maesako, Takasuke Miyazaki, Toshiro Ijuin, Shingo Maeda, Noboru Taniguchi","doi":"10.1016/j.joca.2024.08.005","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the humeral head bone volume of patients with cuff tear arthropathy (CTA) and examine the therapeutic effect of zoledronate in a rat modified model of CTA (mCTA).Design: The bone mass in patients with CTA was measured using Hounsfield units from CT images. The mCTA was induced by transecting the rotator cuff, biceps brachii tendon, and superior half of the joint capsule in adult rat shoulders. A single subcutaneous injection of zoledronate was followed by bone histomorphometry and immunohistochemistry of the humeral head, as well as the Murine Shoulder Arthritis Score (MSAS) assessment.Results: The humeral head bone volume was decreased in patients with CTA. In the mCTA model, M1 macrophages were increased in the synovium and were decreased by zoledronate treatment. The increased expressions of TNF-α, IL-1β and IL-6 in mCTA synovium and articular cartilage were suppressed in the zoledronate-treated mCTA group. The expression of catabolic enzymes in the articular cartilage and MSAS showed similar results. The zoledronate-treated mCTA group showed a decreased subchondral bone collapse with a decreased RANKL/OPG expression ratio and a suppressed number of osteoclasts compared with the control mCTA group. The enhanced expressions of HMGB1 and S100A9 in the mCTA shoulders were eliminated in the zoledronate-treated mCTA group.Conclusions: The humeral head subchondral bone was decreased in patients with CTA. In the mCTA model, the collapse and osteoarthritic changes were prevented by zoledronate administration. Zoledronate seemed to suppress the number of M1 macrophages in the synovium and osteoclasts in the subchondral bone.","PeriodicalId":19654,"journal":{"name":"Osteoarthritis and Cartilage","volume":" ","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoarthritis and Cartilage","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.joca.2024.08.005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the humeral head bone volume of patients with cuff tear arthropathy (CTA) and examine the therapeutic effect of zoledronate in a rat modified model of CTA (mCTA).

Design: The bone mass in patients with CTA was measured using Hounsfield units from CT images. The mCTA was induced by transecting the rotator cuff, biceps brachii tendon, and superior half of the joint capsule in adult rat shoulders. A single subcutaneous injection of zoledronate was followed by bone histomorphometry and immunohistochemistry of the humeral head, as well as the Murine Shoulder Arthritis Score (MSAS) assessment.

Results: The humeral head bone volume was decreased in patients with CTA. In the mCTA model, M1 macrophages were increased in the synovium and were decreased by zoledronate treatment. The increased expressions of TNF-α, IL-1β and IL-6 in mCTA synovium and articular cartilage were suppressed in the zoledronate-treated mCTA group. The expression of catabolic enzymes in the articular cartilage and MSAS showed similar results. The zoledronate-treated mCTA group showed a decreased subchondral bone collapse with a decreased RANKL/OPG expression ratio and a suppressed number of osteoclasts compared with the control mCTA group. The enhanced expressions of HMGB1 and S100A9 in the mCTA shoulders were eliminated in the zoledronate-treated mCTA group.

Conclusions: The humeral head subchondral bone was decreased in patients with CTA. In the mCTA model, the collapse and osteoarthritic changes were prevented by zoledronate administration. Zoledronate seemed to suppress the number of M1 macrophages in the synovium and osteoclasts in the subchondral bone.

查看原文本刊更多论文

唑来膦酸钠能缓解肩袖撕裂关节病大鼠模型中软骨下骨塌陷和关节软骨退化。

目的评估袖带撕裂关节病（CTA）患者的肱骨头骨量，并研究唑来膦酸钠在大鼠改良CTA模型（mCTA）中的治疗效果：设计：利用CT图像中的Hounsfield单位测量CTA患者的骨量。通过横断成年大鼠肩部的肩袖、肱二头肌肌腱和上半关节囊诱导 mCTA。皮下注射一次唑来膦酸钠后，对肱骨头进行骨组织形态测量和免疫组化，并进行小鼠肩关节炎评分（MSAS）评估：结果：CTA患者的肱骨头骨量减少。在 mCTA 模型中，滑膜中的 M1 巨噬细胞增加，唑来膦酸盐治疗后巨噬细胞减少。唑来膦酸钠治疗的mCTA组抑制了TNF-α、IL-1β和IL-6在mCTA滑膜和关节软骨中的表达。关节软骨和MSAS中分解代谢酶的表达也显示出相似的结果。与对照组相比，唑来膦酸钠处理的 mCTA 组软骨下骨塌陷减少，RANKL/OPG 表达比降低，破骨细胞数量减少。唑来膦酸钠处理的 mCTA 组消除了 mCTA 肩部 HMGB1 和 S100A9 表达增强的现象：结论：CTA患者的肱骨头软骨下骨减少。结论：CTA 患者的肱骨头软骨下骨减少，在 mCTA 模型中，服用唑来膦酸盐可防止塌陷和骨关节炎变化。唑来膦酸盐似乎能抑制滑膜中M1巨噬细胞和软骨下骨中破骨细胞的数量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Osteoarthritis and Cartilage 医学-风湿病学

CiteScore

11.70

自引率

7.10%

发文量

802

审稿时长

52 days

期刊介绍： Osteoarthritis and Cartilage is the official journal of the Osteoarthritis Research Society International. It is an international, multidisciplinary journal that disseminates information for the many kinds of specialists and practitioners concerned with osteoarthritis.